Objectif Cardiovascular disease still represents the Killer No.1 in the EU accounting for substantial morbidity/mortality and health care cost. Heart valve replacement represents the most common surgical therapy for valvular heart disease with almost 200.000 annual implantations worldwide. Currently, heart valve prosthesis-associated problems occur in 30-35% of patients within 10 years, frequently necessitating risky re-operations. A particularly severe problem relates to children with congenital heart defects (1% of all newborns) who cannot be treated efficiently due to the lack of growths of the clinically available “artificial” valve prostheses. The principal objective of the LifeValve project is to develop a new therapeutic strategy to treat heart valve disease patients more efficiently. Two novel life science technologies will be combined: tissue engineering and minimally invasive implantation technology. In particular, the scientific and technological approach of the LifeValve project is to develop a clinically relevant tissue engineered living heart valve, with the capacity of regeneration and growths which can be implanted by minimally invasive catheter technology. First clinical trials will be enrolled in paediatric patients addressing the currently unmet dramatic medical need for growing implants. A highly interdisciplinary approach combines basic sciences, medical research, engineering and clinical practice. In addition, close industry-academia collaborations are integrated. It is expected that new knowledge applicable for a much broader field of cardiovascular diseases will be generated by the unique combination of consortium partners each representing opinion leaders in their fields. The consortium is compact comprising all the necessary expertise and skills to realize the precisely planned work in a short period of time.The close collaboration of the well interconnected LifeValve consortium will most efficiently contribute to an added value for the EU. Champ scientifique social sciencessociologydemographymortalitymedical and health sciencesmedical biotechnologytissue engineeringmedical and health sciencesclinical medicinecardiologycardiovascular diseasesmedical and health sciencesmedical biotechnologyimplants Mots‑clés Regenerative medicine cardiovascular disease heart valve tissue engineering Programme(s) FP7-HEALTH - Specific Programme "Cooperation": Health Thème(s) HEALTH-2009-1.4-2 - Regeneration of tissue using bio-compatible materials and cells Appel à propositions FP7-HEALTH-2009-single-stage Voir d’autres projets de cet appel Régime de financement CP-IP - Large-scale integrating project Coordinateur University of Zurich Contribution de l’UE € 2 470 000,00 Adresse RAMISTRASSE 71 8006 ZURICH Suisse Voir sur la carte Type d’activité Higher or Secondary Education Establishments Contact administratif Simon Philipp Hoerstrup (Prof.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée Participants (7) Trier par ordre alphabétique Trier par contribution de l’UE Tout développer Tout réduire DEUTSCHES HERZZENTRUM BERLIN Allemagne Contribution de l’UE € 3 142 372,00 Adresse AUGUSTENBURGER PLATZ 1 13353 Berlin Voir sur la carte Région Berlin Berlin Berlin Type d’activité Higher or Secondary Education Establishments Contact administratif Boris Schmitt (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée TECHNISCHE UNIVERSITEIT EINDHOVEN Pays-Bas Contribution de l’UE € 1 784 000,00 Adresse GROENE LOPER 3 5612 AE Eindhoven Voir sur la carte Région Zuid-Nederland Noord-Brabant Zuidoost-Noord-Brabant Type d’activité Higher or Secondary Education Establishments Contact administratif Frank Baaijens (Prof.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée MEDIZINISCHE UNIVERSITAET WIEN Autriche Contribution de l’UE € 215 480,00 Adresse SPITALGASSE 23 1090 Wien Voir sur la carte Région Ostösterreich Wien Wien Type d’activité Higher or Secondary Education Establishments Contact administratif Gerald Maurer (Prof.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée pfm Produkte fur die Medizin AG Allemagne Contribution de l’UE € 201 000,00 Adresse Wankelstr. 60 50996 Cologne Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Jens Nikelski (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée XELTIS AG Suisse Contribution de l’UE € 850 500,00 Adresse MUHLEBACHSTRASSE 26 8008 ZURICH Voir sur la carte Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif René Stenger (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée XELTIS BV Pays-Bas Contribution de l’UE € 1 146 000,00 Adresse DE LISMORTEL 31 R2 06 CAT BUILD 5612 AR Eindhoven Voir sur la carte Région Zuid-Nederland Noord-Brabant Zuidoost-Noord-Brabant Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Contact administratif Martijn Cox (Mr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée DEBRECENI EGYETEM Hongrie Contribution de l’UE € 67 000,00 Adresse EGYETEM TER 1 4032 Debrecen Voir sur la carte Région Alföld és Észak Észak-Alföld Hajdú-Bihar Type d’activité Higher or Secondary Education Establishments Contact administratif Laszlo Balkay (Dr.) Liens Contacter l’organisation Opens in new window Site web Opens in new window Coût total Aucune donnée
